key: cord-0924918-byr1xz0f authors: Sullivan, Michael; Bouffet, Eric; Rodriguez‐Galindo, Carlos; Luna‐Fineman, Sandra; Khan, Muhammad Saghir; Kearns, Pam; Hawkins, Douglas S.; Challinor, Julia; Morrissey, Lisa; Fuchs, Jörg; Marcus, Karen; Balduzzi, Adriana; Basset‐Salom, Luisa; Caniza, Miguela; Baker, Justin N.; Kebudi, Rejin; Hessissen, Laila; Sullivan, Richard; Pritchard‐Jones, Kathy title: The COVID‐19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP‐E, SIOP‐PODC, IPSO, PROS, CCI, and St Jude Global date: 2020-05-13 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.28409 sha: 8fbc4196156008369f06414c6500d2e165c0b0c6 doc_id: 924918 cord_uid: byr1xz0f The COVID‐19 pandemic is one of the most serious global challenges to delivering affordable and equitable treatment to children with cancer we have witnessed in the last few decades. This Special Report aims to summarize general principles for continuing multidisciplinary care during the SARS‐CoV‐2 (COVID‐19) pandemic. With contributions from the leadership of the International Society for Pediatric Oncology (SIOP), Children's Oncology Group (COG), St Jude Global program, and Childhood Cancer International, we have sought to provide a framework for healthcare teams caring for children with cancer during the pandemic. We anticipate the burden will fall particularly heavily on children, their families, and cancer services in low‐ and middle‐income countries. Therefore, we have brought together the relevant clinical leads from SIOP Europe, COG, and SIOP‐PODC (Pediatric Oncology in Developing Countries) to focus on the six most curable cancers that are part of the WHO Global Initiative in Childhood Cancer. We provide some practical advice for adapting diagnostic and treatment protocols for children with cancer during the pandemic, the measures taken to contain it (e.g., extreme social distancing), and how to prepare for the anticipated recovery period. The COVID-19 pandemic presents an unprecedented global threat to the safe and effective care for children with cancer. In this rapidly changing and uncertain healthcare landscape, there is an urgent need among health professionals and families for informed guidance on the range of reasonable and safe adaptations to their services and cancer treatment, while protecting the health and safety of staff, patients, and families. This rapid global response from the international childhood cancer community aims to provide pragmatic solutions for the problems being faced by our medical and nursing colleagues for the care of children with cancer, regardless of where a child may live. It is the international consensus that, wherever possible, children presenting with a likely diagnosis of cancer during this pandemic should undergo a clinical assessment and appropriate investigations to establish a confirmed diagnosis and be offered effective therapy within the resources available while mitigating against the risk of exposure to COVID-19. The WHO Global Initiative for Childhood Cancer (GICC), launched in 2018, has set an ambitious goal of improving survival rates for the 90% of the world's children who live in low-and middle-income countries (LIMC) to 60% by 2030. 1, 2 The GICC has identified six common index cancers-acute lymphoblastic leukemia (ALL), Burkitt lymphoma (BL), Hodgkin lymphoma (HL), retinoblastoma, Wilms tumor, and lowgrade gliomas (LGGs)-all have a very good prognosis in high-income countries (HICs) and can be treated with curative intent in low-and middle-income countries (LMICs), using established standards of care or resource-adapted treatment regimens such as those previously published by the SIOP-PODC (Pediatric Oncology in Developing Countries) group. 3, [4] [5] [6] [7] [8] Here our specific focus is on these index cancers as they account for the majority of cancers seen in HIC and LMICs, and the core principles for care and treatment of these cancers are generalizable across most other cancers seen in childhood. It is already clear that maintaining services as usual during the COVID-19 pandemic is, in many settings, no longer possible. 9 There is an urgent need for all healthcare providers to evaluate their pathways of care to ensure the continuity of curative treatments and palliative care as effectively as possible. Consideration must be given to how families access care in the presence of serious lockdowns and curfews and service delivery may need to be adapted to availability of qualified staff and suitable facilities. Moreover, in this time of uncertainty and fear, support for patients and their families at diagnosis and during treatment is crucial to ensure they can complete treatment safely. Just as importantly, as a professional child cancer community, we must advocate on behalf of the healthcare workforce to protect the health and safety of nursing, medical staff, and support staff. It is their availability that will ensure that children with cancer will survive this pandemic. Here we provide a rapidly formed international clinical consensus, based on current experience and previous evidence (where available), to suggest "reasonable" modifications to adapt child cancer services and treatments, should services and healthcare teams become overwhelmed by pandemic demand. We also provide advice on preparing for the recovery period, where, sadly, many late diagnoses of childhood cancers can be anticipated from limited pandemic-related access to health care and public fear of infection inhibiting parents seeking early medical assessment of symptoms in their child. Over the three weeks from March Supplement I and Supporting Information Tables S1-S6 Disease-specific guidance for (1) acute lymphoblastic leukemia, (2) Burkitt lymphoma, (3) Hodgkin lymphoma, (4) retinoblastoma, (5) Wilms tumor, and (6) low-grade glioma. Information Tables S7-S9 Specialty and service-specific guidance; (7) Our guidance is set out in this paper and two accompanying supplements whose detailed contents are described in Table 1 . The true impact of COVID-19 infection on children undergoing cancer treatment is at present unknown. Here, we recommend the principle that the standards of care for the diagnosis, treatment, and supportive care for children with cancer should not be compromised or electively modified during the pandemic, if at all possible. Globally, the majority of child cancer services are located within combined adult and pediatric hospitals. In these centers, the risk of cross infection of healthcare staff and patients may be very high, and access to diagnostic services such as radiology, pathology, and treatment services, specifically surgery and radiotherapy, may become radically reduced in addition to a redistribution of resources needed for COVID-19 adult patients. If resource constraints mandate treatment modification, these should be done by a whole service approach rather than by individual clinical decision-making and should ideally be endorsed by institutional governance or a regional/national professional organization. We advise all cancer centers to adopt an anticipatory and planned process to adapt their service to potential resource limitations (Lombardy experience, see below and Supplement II). It is necessary to limit patient visits to clinics and hospital admissions such as the temporary cessation of routine surveillance and survivorship clinics to release medical and nursing staff for frontline clinical care. Where possible, all elements of cancer treatment should continue without modification unless resources become overwhelmed. We recommend maintaining lists of cases where care has been adapted and to develop a prioritized approach to review care when normal service capacity resumes. Colleagues in charge of services in the main childhood cancer center serving the Lombardy region, Northern Italy, have provided highly practical information on how they have managed to deliver usual anticancer care while minimizing transmission of COVID-19 (Supplement II). 10 The crucial factors for managing the overwhelming service The emerging experience from regions with high community trans- Here we set out reasonable and safe modifications to the diagnosis and treatment of children with cancer in centers with significant pandemicrelated resource constraints. As there is no evidence base to inform or guide cancer care during a pandemic, these recommendations are formed by collective expert opinion and based on the principles of pediatric oncology. Moreover, there is no current evidence to support the elective reduction in cancer treatment to prevent or mitigate COVID-19, but deferring elective high-risk treatments may improve patient safety and preserve service capacity to meet pandemic demand. All children suspected of having cancer should be investigated without delay. Because many elements of later treatment depend upon the thoroughness of disease diagnosis, we recommend following existing institutional protocols and standards of care (SOC) to confirm a diagnosis, staging, and risk stratification, which will inform treatment beyond the pandemic. We can envisage circumstances where access to SOC diagnostic investigations may be limited by service constraints. Where a patient presents with advanced cancer and concurrent COVID-19 (either symptomatic or detected on screening), the essential investigations should be done to establish an accurate cancer diagnosis, and interim therapy to control disease may be a safe approach and permit recovery from COVID-19 before commencing disease-directed treatment. In nonemergency presentations with concurrent COVID-19, such as an abdominal mass, intraocular retinoblastoma, or low-stage Hodgkin lymphoma, it is reasonable and safe to defer diagnostic investigations until the child has recovered and proceed with resource-adapted investigations as best can be achieved. Multidisciplinary tumor board meetings should continue for decisionmaking, if necessary, through phone/teleconferencing to ensure social distancing. We are concerned that children with the early clinical signs of cancer may remain in the community and not be referred or present for investigation due to travel restrictions, fear of presenting to hospital or family financial issues. Sadly, there is already evidence of delayed presentation of acute illness in children in high-prevalence areas. 21 ALL is the most common single childhood cancer, with the longest duration of treatment; hence, many cancer services will experience some COVID-19-related disruption to the care of children with ALL during the pandemic. Few COVID-19-positive ALL cases have been reported so far, and the clinical course of those that have been described is of a mild to moderately severe respiratory syndrome, although anecdotal reports of severe infections and fatal outcomes are emerging. 15, 16 Thus, the major threat to children with ALL may be COVID-19-related interruption of treatment, or in some settings, treatment noncompletion. We recommend children presenting with ALL undergo full investigation to establish the diagnosis and risk stratification and com- Burkitt lymphoma (BL) is the most aggressive malignancy seen in childhood; endemic and sporadic BL often present with advanced disease where there is a high risk of immediate treatment-related complications. In resource-poor settings, children may present with advanced disease and significant comorbidity, especially poor nutrition and concurrent chronic infection. 4, 24 BL is exquisitely sensitive to chemotherapy, and even advanced disease can be cured if treated to completion with careful supportive care. At diagnosis in fully resourced and HIC settings with an emergency presentation, no pandemic modifications are recommended for the initial assessment and diagnosis, even if a child presents with concurrent COVID-19. In resource-limited settings especially in endemic LIC regions, a simplified assessment based on the constellation of clinical features, a minimally invasive biopsy and diagnostic imaging with chest X-ray and ultrasound (US) is sufficient to establish a safe diagnosis and commence supportive care and therapy (Supplement I; Supporting Information Table S2 ). 25 We recommend all children and adolescents presenting with progressive lymphadenopathy undergo immediate clinical evaluation and the best available diagnostic imaging and biopsy. When treated with chemotherapy alone, or chemotherapy and radiotherapy, classical HL has an excellent chance of cure, even in resource-limited settings. 26, 27 However, like other childhood cancers with an excellent prognosis, the treatment of HL is risk stratified, based on disease stage, diagnostic risk factors, and the early disease response. 28 When diagnosed early and treated in a well-resourced setting, retinoblastoma is nearly always cured, so the paramount considerations are the preservation of vision, the preservation of the globe, and the determination of a genetic predisposition. 6, [33] [34] [35] [36] However, in many LMIC settings, retinoblastoma presents with advanced disease, with extraocular extension and local or distant metastasis, which carry a poor prognosis. 37, 38 A pandemic-adapted approach to the diagnosis and management of intra-and extraocular retinoblastoma in various resource settings is discussed in Supplement I and listed in Supporting Information Table S4 . Intraocular retinoblastoma requires access to an experienced ophthalmologist for an immediate examina-tion underanesthesia (EUA) to determine the intraocular extent of disease (cT1-CT3) and laterality, as this will determine treatment with either local therapy or local and systemic chemotherapy. Routine neuroimaging (MRI) for unilateral intraocular retinoblastoma could be deferred unless there is involvement of the optic nerve or a suspicion of extraocular involvement. 39 Given the likely resource constraints for interventional radiology and prolonged anesthesia, services should consider deferring intraarterial chemotherapy programs. In resourcelimited settings, most patients with advanced intraocular disease and no salvageable vison will require immediate enucleation to control disease followed by systemic chemotherapy. 33, 36 We recommend standard post-enucleation chemotherapy without dose modification as an outpatient. 37 Guidance is provided in Supplement I and Supporting Information Table S4a and b, for posttreatment surveillance with a modified frequency of examination and follow-up. Pandemic-related service constraints will require a simplified but safe approach to the treatment of Wilms tumor. Sequential clinical trials from SIOP and the COG have adopted a risk-stratified approach to the treatment of Wilms tumor using clinical (SIOP and COG) and molecular (COG) risk factors to minimize treatment-related toxicity while achieving cure rates of over 90%. 40 The SIOP approach has formed the basis for a clinical guideline adapted for use in low-income countries. 7 During this COVID-19 pandemic, elements of these approaches may ing to the initial (COG or SIOP-based) management approach adopted. Detailed guidance for the adapted management of infants < 6 months, bilateral and metastatic disease is given in Supplement I and Supporting Information Table S5 . For children with LGG receiving chemotherapy, the recommendation is to continue the planned treatment without modification. However, some temporary changes could be considered in order to reduce hospital visits (Supplement I; Supporting Information Although there is a trend to recommend systematic biopsies of all suspected optic pathway gliomas outside the context of NF1, the current situation may influence surgical practice and decision-making. Radiotherapy plays an essential role in the cure of many tumors in Table S7 ) outlines levels of evidence for modified and condensed treatment regimens in each pediatric disease. Palliative cases may present with urgent symptoms. When these can be managed medically, this should be considered but where radiotherapy is required, hypofractionation should be strongly considered. Recommendations for childhood cancer surgery need to be tailored according to the COVID-19 prevalence and health system capacity. Children with high-risk cancers represent a particularly vulnera- Advice on the use of PPE during the COVID-19 pandemic is evolving and differs between countries. 63 Reuse of eyewear and N95 masks may be acceptable in certain circumstances, while acknowledging that this may impact on their effectiveness. 64 The WHO has issued recent advice on the use of masks in communities, during home care, and in healthcare settings. 65 Healthcare workers, patients, families, and the wider community must, as a minimum, follow their national government guidance. Centers are urged to revise their use of blood products and transfusion thresholds while adapting policies for safe and adequate blood supplies because measures to "shelter-in-place" and physical distancing are having a serious impact on blood donations. 66, 67 In many settings, there may be adequate supplies of long-life products such as red cells, but supplies of short life products especially platelets are at risk, and in LMICs, families are resorting to social media to find donors. In asymptomatic children, the safe threshold for red cell transfusion is Hb > 7.0 g/dL. The threshold for prophylactic platelet transfusion in patients with no risk factors for bleeding is recommended as 10 × 10 9 /L. For procedures, the platelet threshold for lumbar puncture (LP) for a new diagnosis of ALL is recommended at 50 × 10 9 /L and 20 × 10 9 /L for subsequent LPs; for bone marrow aspirate 10 × 10 9 /L, and for bone marrow biopsy, it is 20 × 10 9 /L. 68 Platelet requirements for surgical procedures vary according to the intervention but should be reviewed with the surgical teams. Centers using general anesthesia for painful procedures should continue to provide these, especially for interventional biopsies, bone marrow aspirates, and LPs. Where access is limited or compromised by service capacity issues, centers should adopt policies for safe and effective sedation with appropriate patient monitoring and postprocedure supervision. Parents experience a high level of anxiety due to the lack of specific information on the real potential risk for children and adolescents with cancer as well as the uncertainty related to the continuity of their The longer-term impact of the COVID-19 pandemic on pediatric oncology trials remains to be seen. Many trials will have delayed recruitment and the time to be completed will need to be extended and the impact on trial outcomes of the necessary protocol deviations to protect patient from exposure to COVID-19 will need future evaluation. There is a paucity of data on the clinical manifestations and outcome of COVID-19 in children being treated for or having recently completed cancer. Given the rarity and spectrum of childhood cancers, it is unlikely that any single center will see more than a few sporadic cases This global effort to accrue and evaluate data on the incidence and clinical course of COVID-19 in children is welcome and essential, and all are encouraged to report their case experience. We are aware of similar registries being set up in some countries and welcome collaboration to develop plans for coanalyses. The global pandemic of infection with SARS-CoV-2 has presented the international childhood cancer community with unforeseen challenges with little time to prepare contingency plans. Ironically, this coincides with only the second year of a global effort, led by the WHO, to improve childhood cancer survival rates in LMICs to 60% by 2030. Even for those countries who had started to implement changes to meet this survival target, their national cancer plans were not written to take account of the possibility of their national healthcare system being overwhelmed by a pandemic such as the world now faces in COVID-19. We have brought together clinical experts from around the world to provide a "rapid response" to help those caring for children with cancer and their families in the front line. This article and associated supplements are intended to offer temporary pragmatic solutions for clinicians facing constraints in the resources they normally have available, recognizing that almost 90% of the world's children with cancer live in LMICs. 2 The overall message is that the planned diagnosis and treatment of children with cancer should continue to be delivered in as timely a fashion as possible and with as few modifications as necessary, while taking account of patient safety and service constraints. The message also needs to go out to parents that they should continue to seek medical advice if they have serious concerns about the health of their child. Early evidence is that parents are staying away from emergency rooms and medical assessments, raising the concern that there may be increased toxic deaths on treatment and a future surge in late presentations of new childhood cancers. In considering treatment modifications for the six most curable should not prevent seeking medical assessment if they have serious concerns about their child's health. 21 It is essential that the global pediatric oncology community aims from the outset to learn as much as possible from this pandemic. A full understanding of who is at risk of developing serious COVID-19 disease and how to prevent and treat this can only come from a global effort to capture detailed prospective data. We urge all services to make full use of the St Jude-SIOP platform and registry to achieve this. 73, 74 We hope there will be some positive changes in ways of working that may endure, if they are shown to be better for patients, such as increased use of oral therapies and telemedicine. Careful documentation and prospective evaluation of these treatment and service changes is needed to ensure this. More worrying is the potential for children with cancer to become indirect victims of the COVID-19 pandemic, due to late diagnosis and disrupted therapies. Epidemiological research to monitor incidence and survival across this pandemic will be critical to understanding the extent to which this occurs and to plan actions for recovery. Childhood cancer parents' organizations can play an important role in reassuring parents of children with known or suspected cancer to seek prompt clinical assessment and by disseminating, in cooperation with healthcare professionals, a clear and accessible message. Finally, we would like to thank all of our colleagues for coming together so quickly to create this publication, and trust that you can all continue care of your patients while staying safe. Childhood cancer burden: a review of global estimates A framework to develop adapted treatment regimens to manage pediatric cancer in low-and middle-income countries: the Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP) Pediatric oncology in developing countries. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: a proposal Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer SIOP PODC: clinical guidelines for the management of children with Wilms tumour in a low income setting SIOP PODC adapted treatment guidelines for low grade gliomas in low and middle income settings Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia Systematic review of COVID-19 in children show milder cases and a better prognosis than adults. Acta Paediatr Oslo Nor 1992 Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics Detection of Covid-19 in children in early SARS-CoV-2 infection in Children Coronavirus disease 2019 and children Flash Survey on SARS-CoV-2 infections in pediatric patients on anti-cancer treatment SARS-CoV-2 infection in children Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state Prolonged shedding of human coronavirus in hematopoietic cell transplant recipients: risk factors and viral genome evolution How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi Burkitt's lymphoma Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma Pediatric Hodgkin lymphoma ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma Improving the prognosis of pediatric Hodgkin lymphoma in developing countries: a Moroccan Society of Pediatric Hematology and Oncology study Hodgkin's disease in Indian children: outcome with chemotherapy alone Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India Study of unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: a children's oncology group study Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries Management of advanced uni-or bilateral retinoblastoma with macroscopic optic nerve invasion Delayed Enucleation with neoadjuvant chemotherapy in advanced intraocular unilateral retinoblastoma: AHOPCA II, a prospective, multi-institutional protocol in Central America Treatment of nonmetastatic unilateral retinoblastoma in children Advances in Wilms tumor treatment and biology: progress through international collaboration Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group Single agent carboplatin for pediatric low-grade glioma: a retrospective analysis shows equivalent efficacy to multiagent chemotherapy Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Running a radiation oncology department at the time of coronavirus: an Italian experience COVID-19: global radiation oncology's targeted response for pandemic preparedness Radiotherapy in the time of the Coronavirus pandemic: when less is better Letter from Italy: first practical indications for radiation therapy departments during COVID-19 outbreak COVID-19 rapid guideline: delivery of radiotherapy Radiotherapy in a time of crisis Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) Consensus guidelines for managing the airway in patients with COVID-19 COVID-19 pandemic: perspectives on an unfolding crisis Palliative care in humanitarian crises: always something to offer Supporting the health care workforce during the COVID-19 global epidemic Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID19) in healthcare settings Three more health workers infected in Ebola outbreak High effectiveness of pandemic influenza A (H1N1) vaccination in healthcare workers from a Portuguese hospital Advocating for the health worker Applying the lessons of SARS to pandemic influenza: an evidence-based approach to mitigating the stress experienced by healthcare workers Water, sanitation, hygiene and waste management for COVID-19 virus. Technical brief European Centre for Disease Prevention and Control. Using face masks in the community; reducing COVI-19 transmission from potentially asymptomatic or presymptomatic people through the use of face masks Considerations for recommending extended use and limited reuse of filtering facepiece respirators in health care settings Advice on the use of masks in the context of COVID-19: interim guidance Red Cross mission continues: We need your help World Health Organsiation. Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19) WHO Interim guidance of Clinical Oncology Clinical Practice Guideline Update Office of Good Clinical Practice (OGCP). FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional, Review Boards Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (USA) Guidance on the Management of clinical trials during the COVID-19 (coronavirus) pandemic, version 2 The Global COVID-19 Observatory and Resource Center for Childhood Cancer St Jude Children's Research Hospital The COVID-19 pandemic: a rapid global response for children with cancer from